Skip to main content

PLERIXAFOR-AFT (AFT Pharmaceuticals Pty Ltd)

Product name
PLERIXAFOR-AFT
Date registered
Evaluation commenced
Decision date
Approval time
123 (255 working days)
Active ingredients
plerixafor
Registration type
New generic medicine
Indication

Plerixafor-AFT is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (MM).

Help us improve the Therapeutic Goods Administration site